CN111449233A - 一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法 - Google Patents
一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法 Download PDFInfo
- Publication number
- CN111449233A CN111449233A CN201910051766.5A CN201910051766A CN111449233A CN 111449233 A CN111449233 A CN 111449233A CN 201910051766 A CN201910051766 A CN 201910051766A CN 111449233 A CN111449233 A CN 111449233A
- Authority
- CN
- China
- Prior art keywords
- bone marrow
- health
- mice
- immunity
- hydrolysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 41
- 241000283690 Bos taurus Species 0.000 title claims abstract description 20
- 230000011132 hemopoiesis Effects 0.000 title claims abstract description 17
- 230000036039 immunity Effects 0.000 title claims abstract description 16
- 230000001737 promoting effect Effects 0.000 title claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000047 product Substances 0.000 title claims description 34
- 239000000413 hydrolysate Substances 0.000 title claims description 15
- 241000699670 Mus sp. Species 0.000 claims abstract description 33
- 230000036541 health Effects 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 20
- 241000237502 Ostreidae Species 0.000 claims abstract description 15
- 235000020636 oyster Nutrition 0.000 claims abstract description 15
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 12
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 12
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 12
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 12
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 12
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 12
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 10
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims abstract description 8
- 108090000526 Papain Proteins 0.000 claims abstract description 8
- 239000004365 Protease Substances 0.000 claims abstract description 8
- 239000002502 liposome Substances 0.000 claims abstract description 8
- 229940055729 papain Drugs 0.000 claims abstract description 8
- 235000019834 papain Nutrition 0.000 claims abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 7
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 7
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 7
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 7
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 7
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 7
- 238000005238 degreasing Methods 0.000 claims abstract description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000010172 mouse model Methods 0.000 claims abstract description 6
- 229910052742 iron Inorganic materials 0.000 claims abstract description 5
- 239000012154 double-distilled water Substances 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 239000012535 impurity Substances 0.000 claims abstract description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 16
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 11
- 244000309464 bull Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000000740 bleeding effect Effects 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000007969 cellular immunity Effects 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000005237 degreasing agent Methods 0.000 claims description 3
- 239000013527 degreasing agent Substances 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 238000005534 hematocrit Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 235000015468 Lycium chinense Nutrition 0.000 claims 1
- 208000007502 anemia Diseases 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 210000001635 urinary tract Anatomy 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000036696 Microcytic anaemia Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000009601 hereditary spherocytosis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/20—Meat products; Meat meal; Preparation or treatment thereof from offal, e.g. rinds, skins, marrow, tripes, feet, ears or snouts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及营养保健品技术领域,特别涉及一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法,优选内蒙古天然牛场新生公牛骨髓,经过脱脂后,利用木瓜蛋白酶进行酶解得到酶解产物,过滤去掉杂质后进行脂质体包被、冷冻干燥,制得骨髓冻干粉,混合以桂圆、枸杞、牡蛎、葛根、维生素c、葡萄糖酸亚铁等辅料制成片剂保健品;选ICR健康小鼠,连续4周喂食低铁饲料与双蒸水,检测血项指标与免疫力指标,建立缺铁贫血模型,将以上步骤制得的片剂每日喂食贫血模型小鼠。结果发现,4周后检测血项指标与免疫力指标,发现小鼠贫血现象显著改善、免疫力显著提高,该保健品对促进机体造血与增强机体免疫力具有显著的效果。
Description
技术领域
本发明涉及营养保健品技术领域,特别涉及促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法。
背景技术
据世界卫生组织(WHO)统计,全球约有30亿人有不同程度贫血,每年因患贫血导致各类疾病而死亡的人数达上千万,中国患贫血的人口概率高于西方国家,在患贫血的人群中女性明显高于男性,老人和儿童高于中青年。现代城镇居民贫血发生率每年以10%~15%的速度增长。
除营养性贫血外,按发病机理可分为:①造血不良性贫血:如再障;②红细胞过度破坏造成的贫血:如遗传性球形红细胞增多症;③失血过多造成的贫血:如溃疡或肿瘤引起的消化道出血等。按细胞大小形态可分为:①大细胞性贫血,如巨幼红细胞性贫血;②正常细胞性贫血,如溶贫、再障等;③单纯小细胞性贫血如慢性感染性贫血;④小细胞低色素性贫血,如缺铁性贫血等。
目前,对于贫血的治疗方法有如下几种,均存在着不同程度的问题。一、药物治疗。一般治疗,食用补血产品:当归补血膏、桑葚蜜膏、阿胶补血膏、健血冲剂、延年益寿精、养血生发胶囊、归芍地黄丸等。食用水果类:龙眼、荔枝、葡萄、樱桃、苹果、桔子,樱桃等等。食用补血蔬菜类:菠菜、胡萝卜、油菜、黄花菜、莲藕、红萝卜。食用五谷类:黑米、黑豆、紫米、糯米等等。但是现有的补血产品食物,见效慢而且只能作为一种辅助产品,并不能完全解决贫血问题,而且停止食用后复发率更高;输血治疗,红细胞输注。少量输注法仅适用于中间型α和β地贫,不主张用于重型β地贫。对于重型β地贫应从早期开始给予中、高量输血,以使患儿生长发育接近正常和防止骨骼病变,但本法容易导致含铁血黄素沉着症;铁鳌合剂去铁治疗,常用去铁胺,可以增加铁从尿液和粪便排出,但不能阻止胃肠道对铁的吸收偶见过敏反应,长期使用可致白内障和长骨发育障碍,剂量过大可引起视力和听觉减退。二、手术治疗:脾切除,脾切除对中间型β地贫的疗效较好,对重型β地贫效果差。脾切除可致免疫功能减弱;造血干细胞移植,异基因造血干细胞移植是目前能根治重型β地贫的方法。如有HLA相配的造血干细胞供者,应作为治疗重型β地贫的首选方法。但是供者数量和匹配率是目前面临的一大问题。三、其他特殊疗法:基因活化治疗,应用化学药物可增加γ基因表达或减少α基因表达,以改善β地贫的状,已用于临床的药物有经基脲、5-氮杂胞苷(5~AZC)、阿糖胞苷、马利兰、异烟肼等,目前正在探索之中。
以上治疗方法均存在一定的局限性,不能从根本上解决骨髓造血的问题,骨髓是人体造血组织,位于长骨骨腔内,负责红细胞、白细胞和血小板的制造。只要骨髓造血能力强,人体就会全身气血旺盛,精力足,免疫力强。
发明内容
针对上述问题中存在的不足之处,本发明提供了一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法。
本发明所述技术方案如下:
一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法,包括如下步骤:(1)高活性的新生公牛骨髓酶解产物冻干粉的制备:优选内蒙古天然牛场新生公牛骨髓洗净后运用食品级脱脂剂进行脱脂,脱脂后选用木瓜蛋白酶,按照1mg/g-10mg/g(其中优选的,终浓度为5mg/g)的浓度室温下进行酶解6h-10h(其中优选的,最佳酶解时间为8h),得到酶解产物,用100um滤网过滤去掉杂质,过滤后的酶解产物与等体积小单室脂质体于玻璃试剂瓶中混匀,室温下振摇玻璃瓶,使得脂质体充分包裹牛骨髓水解产物后进行冷冻干燥,制得骨髓酶解产物冻干粉;
(2)高活性的新生公牛骨髓酶解物保健品片剂的制备:按质量百分比取以下原料制成,取步骤(1)所得的5%-15%冻干粉,混合以10%-30%桂圆、10%-30%枸杞、10%-30%牡蛎、10%-30%葛根、1%-10%维生素c、1%-10%葡萄糖酸亚铁用压片机制成片剂;
(3)缺铁性贫血小鼠模型的建立:选ICR健康小鼠28只,雌雄各半,7只为空白对照组,7只为模型组,7只为冻干粉实验组,7只为市场保健品对照组,先用普通饲料适应性喂养一周,第8天分别测定每只小鼠的血红蛋白(Hb),红细胞数(RBC)、红细胞压积(PVC),作为正常水平数据,供实验对照;然后按照体重比对非空白对照组小鼠倒尾部放血,每20克体重放血0.5克,放血后即开始进行灌胃喂食低铁饲料和双蒸水,空白对照组不做处理喂食普通饲料与水,每周测定Hb、RBC、PVC指标,经4周的耗竭试验模型组与实验组小鼠各项指标均下降40%以上,达到缺铁性贫血模型的要求,造模成功;
(4)模型组小鼠保健品的喂食与结果检测:将步骤(2)所得的保健品片剂喂食小鼠,4周后检测Hb、RBC、PVC与细胞免疫指标。
优选地,步骤(1)中所述的木瓜蛋白酶的浓度为5mg/g,酶解时间为8h。
优选地,步骤(2)中所述的桂圆、枸杞、牡蛎、葛根均磨成粉过200目筛。
优选地,步骤(2)中所述的冻干粉质量百分比为10%、桂圆质量百分比为20%、枸杞质量百分比为20%、葛根质量百分比为20%、牡蛎质量百分比为20%、维生素c质量百分比为5%、葡萄糖酸亚铁质量百分比为5%。
本发明提供的技术方案带来的有益效果是:
1、通过选择新生小公牛骨髓,该年龄段的小牛骨髓造血最为旺盛,处于生长发育的朝阳阶段,各种造血因子、造血干细胞和造血保姆细胞均旺盛生长。而市面上的中大牛骨髓多已脂肪化,造血功能微乎其微。
2、半酶解工艺,市面许多营养品中多是大分子物质(如牛奶),很难被人体直接吸收,这也是许多人补充营养时腹泻的主要原因,保健品虽不至于致人体腹泻,但大分子的营养成分正常人也只能吸收很少一部分,肠胃虚弱的人更甚。精选内蒙古天然牛场新生公牛骨髓,经过脱脂后(避免脂类胆固醇含量过高影响三高人群),利用木瓜蛋白酶水解蛋白质为小分子肽段,直接被小肠绒毛充分吸收,更适合术后和脾胃虚弱人群吸收利用,可迅速增强骨髓造血能力,而且蛋白水解不影响造血相关其它小分子物质活性。
3、脂质体包埋更易吸收,脂质体制备的小牛骨髓冻干粉,从进入到口腔、食道开始就能够高效吸收,吸收效率高。
4、冻干工艺,脱脂水解后的骨髓采用冻干工艺,直接成粉,真空冻干工艺充分保留其原始造血物质,真空过程避免了有效物质的被氧化。
5、最后所得成品不但含有造血相关的多肽、萜类物质、甾类和维生素,更含有小分子核酸类物质可促进造血进程。
6、牡蛎中含有丰富的核苷酸,核苷酸类(嘌呤碱或嘧啶碱基、核糖或脱氧核糖以及磷酸)营养物质通过参与细胞的新陈代谢,改善细胞活力,同时可以促进细胞的再生与修复,为造血干细胞的增殖,血红素与血红蛋白的合成,提供有利条件[5];枸杞,牡蛎中含丰富的精氨酸、赖氨酸,其为造血干细胞、精原细胞染色体的主要碱性组蛋白,因此有利于造血干细胞的基因复制、精子的生长发育;而精氨酸形成的精胺、精脒,又是细胞增殖促进剂,这不仅有利于造血干细胞增殖,也有助于相应器官的细胞代谢。桂圆中含有丰富的铁元素和氨基酸,牡蛎中还含有大量的甘氨酸,其中甘氨酸参与合成甘氨酰胺合成酶参加嘌呤核苷酸合成,有利于造血干细胞的增殖。
7、糖含量极少,不含脂类物质,糖尿病人可放心服用
附图说明
为了更清楚地说明本发明实施例中的技术方案,下面将对实施例描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为空白对照组小鼠与模型组小鼠整体照片,A为空白对照小鼠,B为贫血模型小鼠。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合具体实施例对本发明实施方式作进一步地详细描述。
实施例1
1、一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法:
(1)高活性的新生公牛骨髓酶解产物冻干粉的制备:优选内蒙古天然牛场新生公牛骨髓,洗净晾干,用食品级脱脂剂进行脱脂;向脱脂后的骨髓中按照5mg/g的浓度加入木瓜蛋白酶,室温下酶解8h,,得到酶解产物,100um滤网过滤去掉杂质后与等体积小单室脂质体于玻璃试剂瓶中混匀,室温下振摇玻璃瓶,使得脂质体充分包裹牛骨髓水解产物,后进行冷冻干燥,制得骨髓酶解产物冻干粉;
(2)高活性的新生公牛骨髓酶解物保健品片剂的制备:取步骤(1)所得的冻干粉,混合以桂圆、枸杞、牡蛎、葛根、维生素c、葡萄糖酸亚铁等辅料,其中桂圆、枸杞、牡蛎、葛根洗净晾干后均磨成粉过200目筛备;冻干粉、桂圆、枸杞、牡蛎、葛根的配比如下:冻干粉5%-15%(其中优选的,终质量比为10%)、桂圆10%-30%(其中优选的,终质量比为20%)、枸杞10%-30%(其中优选的,终质量比为20%)、葛根10%-30%(其中优选的,终质量比为20%)、牡蛎10%-30%(其中优选的,终质量比为20%)、维生素c1%-10%(其中优选的,终质量比为5%)、葡萄糖酸亚铁1%-10%(其中优选的,终质量比为5%),按照以上比例将各种材料混合均匀,用压片机制成片剂即得。
2、小鼠缺铁性贫血模型的建立
选ICR健康小鼠36只,雌雄各半,12只为空白对照组,12只为模型组,12只为骨髓酶解物组。
先用普通饲料适应性喂养一周,第8天分别测定每只小鼠的血红蛋白(Hb),红细胞数(RBC)、红细胞压积(PVC),作为正常水平数据,供实验对照。
饲养第8天时按照体重比对非空白对照组小鼠倒尾部放血,每20克体重放血0.5克,放血后进行灌胃喂食低铁饲料和双蒸水,空白对照组不做处理喂食普通饲料与水,每周测定Hb、RBC、PVC指标,经4周的耗竭试验模型组与实验组小鼠各项指标均下降40%以上,达到缺铁性贫血模型的要求,造模成功。
3、骨髓酶解物冻干粉保健品对贫血小鼠模型的修复作用
贫血小鼠模型建立成功后,对骨髓酶解物组小鼠喂食本专利所述的骨髓酶解物,按照体重比,喂食的剂量均为0.05g/克体重/天,连续喂食4周;
4、分别测定模型组、实验组和骨髓酶解物组小鼠的Hb、RBC、PVC与CD3+CD4+细胞比例、CD3+CD8+细胞比例、CD4+/CD8+比值等指标的含量,分析数据。
结果显示模型组的小鼠经过喂食骨髓酶解物冻干粉保健品4周后,Hb、RBC、PVC与CD3+CD4+细胞比例、CD4+/CD8+比值等指标较模型组均有很大程度的提高,表明造血能力与细胞免疫有了显著的提高。
如图1所示,可见贫血模型小鼠毛发明显稀疏,出现脱毛现象,而且毛发没有光泽。
*p<0.05vs空白对照组,#p<0.05vs模型组D0
*p<0.05vs模型组,#p<0.05vs阳性对照组
*p<0.05vs模型组,#p<0.05vs阳性对照组
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (4)
1.一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法,其特征在于,包括如下步骤:(1)高活性的新生公牛骨髓酶解产物冻干粉的制备:优选内蒙古天然牛场新生公牛骨髓洗净后运用食品级脱脂剂进行脱脂,脱脂后选用木瓜蛋白酶,按照1mg/g-10mg/g的浓度室温下进行酶解6h-10h,得到酶解产物,用100um滤网过滤去掉杂质,过滤后的酶解产物与等体积小单室脂质体于玻璃试剂瓶中混匀,室温下振摇玻璃瓶,使得脂质体充分包裹牛骨髓水解产物后进行冷冻干燥,制得骨髓酶解产物冻干粉;
(2)高活性的新生公牛骨髓酶解物保健品片剂的制备:按质量百分比取以下原料制成,取步骤(1)所得的5%-15%冻干粉,混合以10%-30%桂圆、10%-30%枸杞、10%-30%牡蛎、10%-30%葛根、1%-10%维生素c、1%-10%葡萄糖酸亚铁用压片机制成片剂;
(3)缺铁性贫血小鼠模型的建立:选ICR健康小鼠28只,雌雄各半,7只为空白对照组,7只为模型组,7只为冻干粉实验组,7只为市场保健品对照组,先用普通饲料适应性喂养一周,第8天分别测定每只小鼠的血红蛋白,红细胞数、红细胞压积,作为正常水平数据,供实验对照;然后按照体重比对非空白对照组小鼠倒尾部放血,每20克体重放血0.5克,放血后即开始进行灌胃喂食低铁饲料和双蒸水,空白对照组不做处理喂食普通饲料与水,每周测定Hb、RBC、PVC指标,经4周的耗竭试验模型组与实验组小鼠各项指标均下降40%以上,达到缺铁性贫血模型的要求,造模成功;
(4)模型组小鼠保健品的喂食与结果检测:将步骤(2)所得的保健品片剂喂食小鼠,4周后检测Hb、RBC、PVC与细胞免疫指标。
2.根据权利要求1所述的一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法,其特征在于,步骤(1)中所述的木瓜蛋白酶的浓度为5mg/g,酶解时间为8h。
3.根据权利要求1所述的一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法,其特征在于,步骤(2)中所述的桂圆、枸杞、牡蛎、葛根均磨成粉过200目筛。
4.根据权利要求1所述的一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法,其特征在于,步骤(2)中所述的冻干粉质量百分比为10%、桂圆质量百分比为20%、枸杞质量百分比为20%、葛根质量百分比为20%、牡蛎质量百分比为20%、维生素c质量百分比为5%、葡萄糖酸亚铁质量百分比为5%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910051766.5A CN111449233A (zh) | 2019-01-21 | 2019-01-21 | 一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910051766.5A CN111449233A (zh) | 2019-01-21 | 2019-01-21 | 一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111449233A true CN111449233A (zh) | 2020-07-28 |
Family
ID=71671533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910051766.5A Pending CN111449233A (zh) | 2019-01-21 | 2019-01-21 | 一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111449233A (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3944655A (en) * | 1973-09-10 | 1976-03-16 | Viobin Corporation | Process of preparing food products from bones |
JPS59162859A (ja) * | 1983-03-08 | 1984-09-13 | Tsutomu Yamaguchi | 骨髄含有骨粉の製造法 |
CN101220083A (zh) * | 2008-01-29 | 2008-07-16 | 郑州大学 | 合成多肽及其用途 |
JP2008534580A (ja) * | 2005-03-28 | 2008-08-28 | リゲロン アイエヌシー | 蛋白質を包囲するナノリポソームの製造方法及び蛋白質−包囲ナノリポソーム |
CN101322778A (zh) * | 2008-07-22 | 2008-12-17 | 北京康比特体育科技股份有限公司 | 一种补铁双层缓释片及其制备方法 |
CN102397525A (zh) * | 2011-11-11 | 2012-04-04 | 完美(中国)有限公司 | 一种具有改善营养性贫血功能的中药组合物及其制备方法 |
CN102657332A (zh) * | 2012-05-08 | 2012-09-12 | 祁宝红 | 一次性连续生产牦牛骨髓油和超微多肽骨钙粉的制备方法 |
CN102988423A (zh) * | 2012-12-20 | 2013-03-27 | 海南百思特医药科技有限公司 | 一种复方骨肽脂质体注射剂 |
CN108378375A (zh) * | 2018-02-09 | 2018-08-10 | 王清秀 | 人参牛骨髓肽组合物及其应用 |
CN108949880A (zh) * | 2018-08-03 | 2018-12-07 | 吉林大学 | 一种牛脊髓肽的制备方法及其应用 |
-
2019
- 2019-01-21 CN CN201910051766.5A patent/CN111449233A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3944655A (en) * | 1973-09-10 | 1976-03-16 | Viobin Corporation | Process of preparing food products from bones |
JPS59162859A (ja) * | 1983-03-08 | 1984-09-13 | Tsutomu Yamaguchi | 骨髄含有骨粉の製造法 |
JP2008534580A (ja) * | 2005-03-28 | 2008-08-28 | リゲロン アイエヌシー | 蛋白質を包囲するナノリポソームの製造方法及び蛋白質−包囲ナノリポソーム |
CN101220083A (zh) * | 2008-01-29 | 2008-07-16 | 郑州大学 | 合成多肽及其用途 |
CN101322778A (zh) * | 2008-07-22 | 2008-12-17 | 北京康比特体育科技股份有限公司 | 一种补铁双层缓释片及其制备方法 |
CN102397525A (zh) * | 2011-11-11 | 2012-04-04 | 完美(中国)有限公司 | 一种具有改善营养性贫血功能的中药组合物及其制备方法 |
CN102657332A (zh) * | 2012-05-08 | 2012-09-12 | 祁宝红 | 一次性连续生产牦牛骨髓油和超微多肽骨钙粉的制备方法 |
CN102988423A (zh) * | 2012-12-20 | 2013-03-27 | 海南百思特医药科技有限公司 | 一种复方骨肽脂质体注射剂 |
CN108378375A (zh) * | 2018-02-09 | 2018-08-10 | 王清秀 | 人参牛骨髓肽组合物及其应用 |
CN108949880A (zh) * | 2018-08-03 | 2018-12-07 | 吉林大学 | 一种牛脊髓肽的制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3014897C (en) | Nutritional support for animals via administration of an algal derived supplement | |
CN103907936B (zh) | 一种高蛋白组合物及其制备方法和应用 | |
CN109757734A (zh) | 一种多肽口服液及其制备方法 | |
CN110172491B (zh) | 一种多元生物蛋白肽及其制备方法 | |
CN102273710B (zh) | 一种补血的保健饮品 | |
CN104543534A (zh) | 一种富硒鹌鹑蛋饲料添加剂及其制备方法 | |
CN102524420A (zh) | 一种免疫系统配方奶粉的干法生产方法 | |
CN102499290B (zh) | 一种富硒香菇营养奶粉及其制备方法 | |
CN110172106A (zh) | 一种桃胶多糖铁及其应用 | |
CN1586237A (zh) | 一种复方助睡益肠补钙中药保健奶片制备方法 | |
CN108618128A (zh) | 调节免疫力的组合物及其制备方法和应用 | |
CN111449233A (zh) | 一种促进机体造血与增强免疫力的新生牛骨髓酶解物保健品片剂的制备方法 | |
CN104719631A (zh) | 海水工业化养殖大西洋鲑专用维生素营养剂及其制备方法 | |
CN1317033C (zh) | 防治缺铁病的组合物及其生产方法 | |
CN106418067A (zh) | 一种补充体力、缓解疲劳的保健饮料 | |
CN113855764B (zh) | 用于提高机体免疫力的中药复方制剂 | |
CN106333357A (zh) | 海参肠螺旋藻颗粒冲剂及其制备方法 | |
CN110585321A (zh) | 一种用于防治贫血的中药组合物及其制备方法与应用 | |
CN1131000A (zh) | 一种保健饮料 | |
CN104939098A (zh) | 一种增强骨免疫力、补钙锁钙的保健食品及其制备方法 | |
CN108553549A (zh) | 枣杞泡腾片及其制备方法 | |
CN111298099A (zh) | 一种补铁组合物及其制备方法与用途 | |
CN109331039B (zh) | 一种改善营养性贫血的组合物及其应用 | |
CN114990179B (zh) | 一种甲鱼蛋活性肽冻干粉的制备方法及其应用 | |
Zhao et al. | Studies of the relation between the nutritional status of lactating mothers and milk composition as well as the milk intake and growth of their infants in Beijing. Pt. 4. The protein and amino acid content of breast milk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200728 |
|
RJ01 | Rejection of invention patent application after publication |